Tumor-specific CD4+ T cells maintain effector and memory tumor-specific CD8+ T cells

European Journal of Immunology

Volumn 44, Issue 1, 2014, Pages 69-79

  Church, Sarah E ^a,b   Jensen, Shawn M ^a   Antony, Paul A ^c   Restifo, Nicholas P ^d   Fox, Bernard A ^a,b,e  

^a EARLE A CHILES RESEARCH INSTITUTE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Cancer immunotherapy; CD4+ T cell help; Metastatic melanoma; PD 1; T cell

Indexed keywords

CD4 ANTIBODY; CYTOKINE; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN BCL 2; TYROSINASE RELATED PROTEIN 1; CANCER VACCINE; MEMBRANE PROTEIN; OXIDOREDUCTASE; PDCD1 PROTEIN, MOUSE; PROGRAMMED DEATH 1 RECEPTOR; TUMOR ANTIGEN; TYRP1 PROTEIN, MOUSE;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SURVIVAL; CELL TRANSFER; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; MALE; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN METASTASIS; THERAPY EFFECT; TUMOR IMMUNITY; TUMOR VOLUME; ANIMAL; CELL COMMUNICATION; CYTOTOXICITY; GENETICS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; KNOCKOUT MOUSE; MELANOMA, EXPERIMENTAL; METABOLISM; PROCEDURES; TRANSGENIC MOUSE; TRANSPLANTATION; TRENDS; TUMOR MICROENVIRONMENT;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL COMMUNICATION; CELLULAR MICROENVIRONMENT; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; IMMUNOLOGIC MEMORY; IMMUNOTHERAPY, ADOPTIVE; MALE; MELANOMA, EXPERIMENTAL; MEMBRANE GLYCOPROTEINS; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; OXIDOREDUCTASES; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 84892461172     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201343718     Document Type: Article

References (49)

1. Atkins, M. B., Lotze, M. T., Dutcher, J. P., Fisher, R. I., Weiss, G., Margolin, K., Abrams, J. et al., High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 1999. 17: 2105-2116.
2. Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R. et al., Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010. 363: 711-723.
3. Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H. et al., Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 2013. 369: 122-133.
4. Mulé, J. J., Ettinghausen, S. E., Spiess, P. J., Shu, S. and Rosenberg, S. A., Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy. Cancer Res. 1986. 46: 676-683.
5. Dudley, M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L. et al., Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002. 298: 850-854.
6. Hu, H.-M., Poehlein, C. H., Urba, W. J. and Fox, B. A., Development of antitumor immune responses in reconstituted lymphopenic hosts. Cancer Res. 2002. 62: 3914-3919.
7. Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. and June, C. H., Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 2011. 365: 725-733.
8. Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E. et al., Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006. 314: 126-129.
9. Mombaerts, P., Iacomini, J., Johnson, R. S., Herrup, K., Tonegawa, S. and Papaioannou, V. E., RAG-1-deficient mice have no mature B and T lymphocytes. Cell 1992. 68: 869-877.
10. North, R. J., Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J. Exp. Med. 1982. 155: 1063-1074.
11. Gattinoni, L., Finkelstein, S. E., Klebanoff, C. A., Antony, P. A., Palmer, D. C., Spiess, P. J., Hwang, L. N. et al., Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J. Exp. Med. 2005. 202: 907-912.
12. Hinrichs, C. S., Borman, Z. A., Gattinoni, L., Yu, Z., Burns, W. R., Huang, J., Klebanoff, C. A. et al., Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. Blood 2011. 117: 808-814.
13. Klebanoff, C. A., Gattinoni, L., Palmer, D. C., Muranski, P., Ji, Y., Hinrichs, C. S., Borman, Z. A. et al., Determinants of successful CD8+ T cell adoptive immunotherapy for large established tumors in mice. Clin. Cancer Res. 2011. 17: 5343-5352.
14. Dudley, M. E., Yang, J. C., Sherry, R., Hughes, M. S., Royal, R., Kammula, U., Robbins, P. F. et al., Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 2008. 26: 5233-5239.
15. Barth, R. J., Mulé, J. J., Spiess, P. J. and Rosenberg, S. A., Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes. J. Exp. Med. 1991. 173: 647-658.
16. Schoenberger, S. P., Toes, R. E., van der Voort, E. I., Offringa, R. and Melief, C. J., T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998. 393: 480-483.
17. Sun, J. C., Williams, M. A. and Bevan, M. J., CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection. Nat. Immunol. 2004. 5: 927-933.
18. Hu, H. M., Winter, H., Urba, W. J. and Fox, B. A., Divergent roles for CD4+ T cells in the priming and effector/memory phases of adoptive immunotherapy. J. Immunol. 2000. 165: 4246-4253.
19. de Goër de Herve, M.-G., Cariou, A., Simonetta, F. and Taoufik, Y., Heterospecific CD4 help to rescue CD8 T cell killers. J. Immunol. 2008. 181: 5974-5980.
20. Kmieciak, M., Worschech, A., Nikizad, H., Gowda, M., Habibi, M., Depcrynski, A., Wang, E. et al., CD4+ T cells inhibit the neu-specific CD8+ T-cell exhaustion during the priming phase of immune responses against breast cancer. Breast Cancer Res. Treat. 2011. 126: 385-394.
21. LaCelle, M. G., Jensen, S. M. and Fox, B. A., Partial CD4 depletion reduces regulatory T cells induced by multiple vaccinations and restores therapeutic efficacy. Clin. Cancer Res. 2009. 15: 6881-6890.
22. Côté, A. L., Byrne, K. T., Steinberg, S. M., Zhang, P. and Turk, M. J., Protective CD8 memory T cell responses to mouse melanoma are generated in the absence of CD4 T cell help. PLoS ONE 2011. 6: e26491.
23. Tan, J. T., Ernst, B., Kieper, W. C., LeRoy, E., Sprent, J. and Surh, C. D., Interleukin (IL)-15 and IL-7 jointly regulate homeostatic proliferation of memory phenotype CD8+ cells but are not required for memory phenotype CD4+ cells. J. Exp. Med. 2002. 195: 1523-1532.
24. Goldrath, A. W., Bogatzki, L. Y. and Bevan, M. J., Naive T cells transiently acquire a memory-like phenotype during homeostasis-driven proliferation. J. Exp. Med. 2000. 192: 557-564.
25. Cohen, P. A., Kim, H., Fowler, D. H., Gress, R. E., Jakobsen, M. K., Alexander, R. B., Mulé, J. J. et al., Use of interleukin-7, interleukin-2, and interferon-gamma to propagate CD4+ T cells in culture with maintained antigen specificity. J. Immunother. Emphasis Tumor Immunol. 1993. 14: 242-252.
26. Curti, B. D., Ochoa, A. C., Powers, G. C., Kopp, W. C., Alvord, W. G., Janik, J. E., Gause, B. L. et al., Phase I trial of anti-CD3-stimulated CD4+ T cells, infusional interleukin-2, and cyclophosphamide in patients with advanced cancer. J. Clin. Oncol. 1998. 16: 2752-2760.
27. Quezada, S. A., Simpson, T. R., Peggs, K. S., Merghoub, T., Vider, J., Fan, X., Blasberg, R. et al., Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J. Exp. Med. 2010. 207: 637-650.
28. Xie, Y., Akpinarli, A., Maris, C., Hipkiss, E. L., Lane, M., Kwon, E. K. M., Muranski, P. et al., Naive tumor-specific CD4+ T cells differentiated in vivo eradicate established melanoma. J. Exp. Med. 2010. 207: 651-667.
29. Muranski, P., Boni, A., Antony, P. A., Cassard, L., Irvine, K. R., Kaiser, A., Paulos, C. M. et al., Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 2008. 112: 362-373.
30. Schwartzentruber, D. J., Lawson, D. H., Richards, J. M., Conry, R. M., Miller, D. M., Treisman, J., Gailani, F. et al., gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N. Engl. J. Med. 2011. 364: 2119-2127.
31. Robbins, P. F., Dudley, M. E., Wunderlich, J., El-Gamil, M., Li, Y. F., Zhou, J., Huang, J. et al., Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J. Immunol. 2004. 173: 7125-7130.
32. Precopio, M. L., Betts, M. R., Parrino, J., Price, D. A., Gostick, E., Ambrozak, D. R., Asher, T. E. et al., Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses. J. Exp. Med. 2007. 204: 1405-1416.
33. Frankel, T. L., Burns, W. R., Peng, P. D., Yu, Z., Chinnasamy, D., Wargo, J. A., Zheng, Z. et al., Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase. J. Immunol. 2010. 184: 5988-5998.
34. Almeida, J. R., Price, D. A., Papagno, L., Arkoub, Z. A., Sauce, D., Bornstein, E., Asher, T. E. et al., Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J. Exp. Med. 2007. 204: 2473-2485.
35. Hu, H.-M., Winter, H., Ma, J., Croft, M., Urba, W. J. and Fox, B. A., CD28, TNF receptor, and IL-12 are critical for CD4-independent cross-priming of therapeutic antitumor CD8+ T cells. J. Immunol. 2002. 169: 4897-4904.
36. Bos, R. and Sherman, L. A., CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. Cancer Res. 2010. 70: 8368-8377.
37. Bennett, S. R., Carbone, F. R., Karamalis, F., Flavell, R. A., Miller, J. F. and Heath, W. R., Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 1998. 393: 478-480.
38. Janssen, E. M., Droin, N. M., Lemmens, E. E., Pinkoski, M. J., Bensinger, S. J., Ehst, B. D., Griffith, T. S. et al., CD4 +T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. Nature 2005. 434: 88-93.
39. Rapetti, L., Meunier, S., Pontoux, C. and Tanchot, C., CD4 help regulates expression of crucial genes involved in CD8 T cell memory and sensitivity to regulatory elements. J. Immunol. 2008. 181: 299-308.
40. Aubert, R. D., Kamphorst, A. O., Sarkar, S., Vezys, V., Ha, S.-J., Barber, D. L., Ye, L. et al., Antigen-specific CD4 T-cell help rescues exhausted CD8 T cells during chronic viral infection. Proc. Natl. Acad. Sci. USA 2011. 108: 21182-21187.
41. Fuse, S., Tsai, C. Y., Molloy, M. J., Allie, S. R., Zhang, W., Yagita, H. and Usherwood, E. J., Recall responses by helpless memory CD8+ T cells are restricted by the up-regulation of PD-1. J. Immunol. 2009. 182: 4244-4254.
42. Peng, W., Liu, C., Xu, C., Lou, Y., Chen, J., Yang, Y., Yagita, H. et al., PD-1 blockade enhances T cell migration to tumors by elevating IFN-γ inducible chemokines. Cancer Res. 2012. 72: 5209-5218.
43. Nakanishi, Y., Lu, B., Gerard, C. and Iwasaki, A., CD8+ T lymphocyte mobilization to virus-infected tissue requires CD4+ T-cell help. Nature 2009. 462: 510-513.
44. Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J. and Schreiber, R. D., IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001. 410: 1107-1111.
45. Jensen, S. M., Twitty, C. G., Maston, L. D., Antony, P. A., Lim, M., Hu, H.-M., Petrausch, U. et al., Increased frequency of suppressive regulatory T cells and T cell-mediated antigen loss results in murine melanoma recurrence. J. Immunol. 2012. 89: 767-776.
46. Knutson, K. L. and Disis, M. L., Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol. Immunother. 2005. 54: 721-728.
47. Butterfield, L. H., Ribas, A., Dissette, V. B., Amarnani, S. N., Vu, H. T., Oseguera, D., Wang, H.-J. et al., Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin. Cancer Res. 2003. 9: 998-1008.
48. Hu, H. M., Urba, W. J. and Fox, B. A., Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to a type 1 cytokine profile. J. Immunol. 1998. 161: 3033-3041.
49. Quah, B. J. C, Warren, H. S. and Parish, C. R., Monitoring lymphocyte proliferation in vitro and in vivo with the intracellular fluorescent dye carboxyfluorescein diacetate succinimidyl ester. Nat. Protoc. 2007. 2: 2049-2056.